Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBR7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,498
Award facts
- Contract value 100% obligated
- $20,498.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $20,498.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 266 mg/20 mL vials of EXPAREL, a specialty surgical anesthetic product. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, operates under a firm fixed-price structure with no set-aside designation, allowing DMS Pharmaceutical Group to compete directly against other qualified vendors. This award represents one of numerous delivery orders issued to the contractor under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under the PPV-G GEN V program, designated as contract SPE2DR, which was awarded on November 13, 2025, with a ceiling value of $499.999 billion and extends through December 31, 2036. This contract establishes the company as a critical pharmaceutical supplier supporting Department of Defense healthcare operations worldwide, enabling the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to serve military healthcare facilities. The broader PPV-G GEN V acquisition strategy represents a $30.3 billion initiative designed to ensure reliable pharmaceutical supply chains across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBR7?
SPE2DR26FFBR7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FFBR7 worth?
The government has obligated $20,498 on SPE2DR26FFBR7.
Is contract SPE2DR26FFBR7 an order under another contract?
Yes. SPE2DR26FFBR7 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBR7 competed?
The extent of competition for SPE2DR26FFBR7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award